Journal article
Amolpreet Kaur, Parminder Singh, Gifty Singh, Gaurav Mohan, G. Chopra, R. Singh
International Journal of Advances in Medicine, 2021
International Journal of Advances in Medicine, 2021
Semantic Scholar
DOI
Cite
Cite
APA
Click to copy
Kaur, A., Singh, P., Singh, G., Mohan, G., Chopra, G., & Singh, R. (2021). Euglycemic diabetic ketoacidosis - a rare side effect of sodium-glucose co-transporter-2 inhibitor in a patient of type 2 diabetes mellitus with left ventricular dysfunction: a case report. International Journal of Advances in Medicine.
Chicago/Turabian
Click to copy
Kaur, Amolpreet, Parminder Singh, Gifty Singh, Gaurav Mohan, G. Chopra, and R. Singh. “Euglycemic Diabetic Ketoacidosis - a Rare Side Effect of Sodium-Glucose Co-Transporter-2 Inhibitor in a Patient of Type 2 Diabetes Mellitus with Left Ventricular Dysfunction: a Case Report.” International Journal of Advances in Medicine (2021).
MLA
Click to copy
Kaur, Amolpreet, et al. “Euglycemic Diabetic Ketoacidosis - a Rare Side Effect of Sodium-Glucose Co-Transporter-2 Inhibitor in a Patient of Type 2 Diabetes Mellitus with Left Ventricular Dysfunction: a Case Report.” International Journal of Advances in Medicine, 2021.
BibTeX Click to copy
@article{amolpreet2021a,
title = {Euglycemic diabetic ketoacidosis - a rare side effect of sodium-glucose co-transporter-2 inhibitor in a patient of type 2 diabetes mellitus with left ventricular dysfunction: a case report},
year = {2021},
journal = {International Journal of Advances in Medicine},
author = {Kaur, Amolpreet and Singh, Parminder and Singh, Gifty and Mohan, Gaurav and Chopra, G. and Singh, R.}
}
Abstract
A 42 year old female with type 2 diabetes mellitus (T2DM), presented with angina on exertion and left ventricular (LV) dysfunction (global LV ejection fraction (EF)=26%). Patient was subjected to coronary angiography which revealed triple vessel disease. Patient was started on usual standard of care heart failure (HF) medications, including sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin which is promising new class of drug for treating T2DM and HF. Patient was advised myocardial revascularization in form of percutaneous transluminal coronary angioplasty (PTCA). Post angioplasty patient developed metabolic acidosis (high anion gap with normal lactate and increased ketone levels). Patient was diagnosed as case of euglycemic diabetic ketoacidosis (DKA) and patient was treated by volume resuscitation and insulin infusion.
